Evidence Repository - Clinical Genome Resources

The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

Link to SEPIO compliant JSON-LD document

CA290949843

Gene: ITGA2B

Condition: Glanzmann's thrombasthenia

Inheritance Mode: Autosomal recessive inheritance

Link to MONDO

UUID: 27432f6c-0a8e-4dd5-abdc-e3aeb530dae4

HGVS expressions

NM_000419.5:c.1672C>T

NM_000419.3:c.1672C>T

NM_000419.4:c.1672C>T

ENST00000262407.5:c.1672C>T

ENST00000592226.5:n.1145C>T

ENST00000592462.5:n.467C>T

NC_000017.11:g.44380082G>A

CM000679.2:g.44380082G>A

NC_000017.10:g.42457450G>A

CM000679.1:g.42457450G>A

NC_000017.9:g.39812976G>A

NG_008331.1:g.14424C>T

Pathogenic

PVS1 PM3_Supporting PM2_Supporting

PP4

Evidence Links 1

Expert Panel

Platelet Disorders VCEP

Criteria Specification Information

Criteria Specifications for this VCEP

Evidence submitted by expert panel

Platelet Disorders VCEP

The ITGA2B nonsense variant NM_000419.4:c.1672C>T (p.Gln558Ter) introduces a premature termination codon and the resulting mRNA product is predicted to undergo nonsense mediated decay, leading to loss of normal protein function. This variant has been observed in homozygosity in an individual with a platelet aggregation phenotype consistent with Glanzmann's thrombasthenia (GT), however sufficient bleeding phenotype information was not provided to determine if the individual's phenotype is specific for GT. This variant has not been reported in population databases. In summary, this variant meets criteria to be classified as pathogenic for GT. GT-specific criteria applied: PVS1, PM2_Supporting, and PM3_supporting.

PVS1

This variant introduces a termination codon at amino acid position 558 in exon 17/30. The resulting mRNA product is predicted to undergo nonsense mediated decay, leading to loss of normal protein function.

PM3_Supporting

This variant was reported in homozygosity in one individual (CabGT-8 in PMID: 20020534). This homozygous occurrence earns 0.5 points and is sufficient to apply PM3_supporting.

PubMed:20020534

PM2_Supporting

Variant not observed in gnomAD v2.1.1 or v3.

PP4

This variant was reported in homozygosity in one individual (originally reported as CabGT-8 in PMID: 20020534, additional information reported as 279 — Patient 8 in Glanzmann's Thrombasthenia Database) with a platelet aggregation phenotype consistent with Glanzmann's Thrombasthenia (abnormal response to multiple agonists and normal response to ristocetin). However, sufficient phenotypic information (bleeding phenotype, surface expression, etc.) to meet PP4 were not provided.

Approved on: 2020-08-27

Published on: 2021-01-22

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.